More threads by David Baxter PhD

David Baxter PhD

Late Founder
FDA approves Lyrica for fibromyalgia

Pfizer has announced that the Food and Drug Administration (FDA) approved Lyrica® (pregabalin) capsules CV for the management of fibromyalgia.

Characterized by chronic widespread pain that can be relentless, fibromyalgia is usually accompanied by poor sleep, stiffness, fatigue, depression and anxiety; sufferers also report experiencing deep tenderness, soreness and flu-like aching. The pain of fibromyalgia can hamper a patient's ability to work and often results in increased medical costs and disability.

Fibromyalgia is thought to result from neurological changes in how patients perceive pain, specifically a heightened sensitivity to stimuli that are not normally painful. Lyrica® binds to a specific protein within overexcited nerve cells and works to calm damaged nerves. This is thought to reduce the level of pain in patients suffering from fibromyalgia, although the exact mechanism of how Lyrica acts in fibromyalgia is not known.

Lyrica® is also approved for the management of neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia, and as an adjunctive therapy for adult patients with partial onset seizures.
 

Similar threads

https://www.formularywatch.com/view/the-fda-approves-ultomiris-for-myasthenia-gravis April 28, 2022 Formulary Watch Vivjoa is an oral therapy and the first for chronic yeast infections. It is expected to be available in the second quarter of 2022. The FDA has approved Vivjoa (oteseconazole capsules), an azole antifungal to reduce the incidence of chronic yeast infection in postmenopausal women. This is the first approval for Mycovia Pharmaceuticals, which is developing therapies for fungal...
Replies
0
Views
198
It used to be thought that children would "grow out of" ADHD by about age 14 or 15. We no know this to be false. Children (correctly) diagnosed with ADHD grow up to be adults with ADHD. That of course may be related more to temperament or emotional sensitivity that to the medication.
Replies
2
Views
2K
FDA Approves Once-Monthly Treatment for Schizophrenia By Caroline Cassels Mar 01, 2013 The US Food and Drug Administration (FDA) has approved long-acting aripiprazole (Abilify Maintena, Otsuka/Lundbeck) for the maintenance treatment of adults with schizophrenia. A once-monthly intramuscular (IM) depot formulation, the drug has the same efficacy and safety profile as the oral formulation, the manufacturers report. The FDA approval follows positive results of a phase 3 double-blind...
Replies
0
Views
1K
FDA Approves Transdermal Patch for Migraine Medscape Medical News Laurie Barclay, MD Jan 18, 2013 The U.S. Food and Drug Administration (FDA) has approved sumatriptan iontophoretic transdermal system (Zecuity, NuPathe Inc) for acute treatment of adults who have migraine with or without aura. The single-use, battery-powered patch offers relief of migraine-related nausea (MRN) as well as migraine headache pain. Of 16 million U.S. adults diagnosed and treated with migraine, 8 million have MRN...
Replies
0
Views
1K
On a lighter note, Steve Martin joked that such a list could include winning online poker.
Replies
1
Views
3K
Top